Brain metastases from NSCLC treated with stereotactic radiotherapy: prediction mismatch between two different radiomic platforms.


Journal

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
ISSN: 1879-0887
Titre abrégé: Radiother Oncol
Pays: Ireland
ID NLM: 8407192

Informations de publication

Date de publication:
01 2023
Historique:
received: 07 03 2022
revised: 28 10 2022
accepted: 18 11 2022
pubmed: 27 11 2022
medline: 8 2 2023
entrez: 26 11 2022
Statut: ppublish

Résumé

Radiomics enables the mining of quantitative features from medical images. The influence of the radiomic feature extraction software on the final performance of models is still a poorly understood topic. This study aimed to investigate the ability of radiomic features extracted by two different radiomic platforms to predict clinical outcomes in patients treated with radiosurgery for brain metastases from non-small cell lung cancer. We developed models integrating pre-treatment magnetic resonance imaging (MRI)-derived radiomic features and clinical data. Pre-radiotherapy gadolinium enhanced axial T1-weighted MRI scans were used. MRI images were re-sampled, intensity-shifted, and histogram-matched before radiomic extraction by means of two different platforms (PyRadiomics and SOPHiA Radiomics). We adopted LASSO Cox regression models for multivariable analyses by creating radiomic, clinical, and combined models using three survival clinical endpoints (local control, distant progression, and overall survival). The statistical analysis was repeated 50 times with different random seeds and the median concordance index was used as performance metric of the models. We analysed 276 metastases from 148 patients. The use of the two platforms resulted in differences in both the quality and the number of extractable features. That led to mismatches in terms of end-to-end performance, statistical significance of radiomic scores, and clinical covariates found significant in combined models. This study shed new light on how extracting radiomic features from the same images using two different platforms could yield several discrepancies. That may lead to acute consequences on drawing conclusions, comparing results across the literature, and translating radiomics into clinical practice.

Sections du résumé

BACKGROUND AND PURPOSE
Radiomics enables the mining of quantitative features from medical images. The influence of the radiomic feature extraction software on the final performance of models is still a poorly understood topic. This study aimed to investigate the ability of radiomic features extracted by two different radiomic platforms to predict clinical outcomes in patients treated with radiosurgery for brain metastases from non-small cell lung cancer. We developed models integrating pre-treatment magnetic resonance imaging (MRI)-derived radiomic features and clinical data.
MATERIALS AND METHODS
Pre-radiotherapy gadolinium enhanced axial T1-weighted MRI scans were used. MRI images were re-sampled, intensity-shifted, and histogram-matched before radiomic extraction by means of two different platforms (PyRadiomics and SOPHiA Radiomics). We adopted LASSO Cox regression models for multivariable analyses by creating radiomic, clinical, and combined models using three survival clinical endpoints (local control, distant progression, and overall survival). The statistical analysis was repeated 50 times with different random seeds and the median concordance index was used as performance metric of the models.
RESULTS
We analysed 276 metastases from 148 patients. The use of the two platforms resulted in differences in both the quality and the number of extractable features. That led to mismatches in terms of end-to-end performance, statistical significance of radiomic scores, and clinical covariates found significant in combined models.
CONCLUSION
This study shed new light on how extracting radiomic features from the same images using two different platforms could yield several discrepancies. That may lead to acute consequences on drawing conclusions, comparing results across the literature, and translating radiomics into clinical practice.

Identifiants

pubmed: 36435336
pii: S0167-8140(22)04561-3
doi: 10.1016/j.radonc.2022.11.013
pii:
doi:

Banques de données

ClinicalTrials.gov
['NCT03940235']

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

109424

Informations de copyright

Copyright © 2022 Elsevier B.V. All rights reserved.

Auteurs

Gianluca Carloni (G)

Division of Radiation Oncology, IEO, European Institute of Oncology, IRCCS, Milan, Italy; "Alessandro Faedo" Institute of Information Science and Technologies (ISTI), National Research Council of Italy (CNR), Pisa, Italy; Department of Information Engineering, University of Pisa, Pisa, Italy.

Cristina Garibaldi (C)

Unit of Radiation Research, IEO, European Institute of Oncology, IRCCS, Milan, Italy.

Giulia Marvaso (G)

Division of Radiation Oncology, IEO, European Institute of Oncology, IRCCS, Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.

Stefania Volpe (S)

Division of Radiation Oncology, IEO, European Institute of Oncology, IRCCS, Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.

Mattia Zaffaroni (M)

Division of Radiation Oncology, IEO, European Institute of Oncology, IRCCS, Milan, Italy. Electronic address: mattia.zaffaroni@ieo.it.

Matteo Pepa (M)

Division of Radiation Oncology, IEO, European Institute of Oncology, IRCCS, Milan, Italy.

Lars Johannes Isaksson (LJ)

Division of Radiation Oncology, IEO, European Institute of Oncology, IRCCS, Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.

Francesca Colombo (F)

Division of Radiation Oncology, IEO, European Institute of Oncology, IRCCS, Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.

Stefano Durante (S)

Division of Radiation Oncology, IEO, European Institute of Oncology, IRCCS, Milan, Italy.

Giuliana Lo Presti (G)

Department of Experimental Oncology, IEO, European Institute of Oncology, IRCCS, Milan, Italy.

Sara Raimondi (S)

Department of Experimental Oncology, IEO, European Institute of Oncology, IRCCS, Milan, Italy.

Lorenzo Spaggiari (L)

Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy; Department of Thoracic Surgery, IEO, European Institute of Oncology, IRCCS, Milan, Italy.

Filippo de Marinis (F)

Division of Thoracic Oncology, IEO, European Institute of Oncology, IRCCS, Milan, Italy.

Gaia Piperno (G)

Division of Radiation Oncology, IEO, European Institute of Oncology, IRCCS, Milan, Italy.

Sabrina Vigorito (S)

Unit of Medical Physics, IEO, European Institute of Oncology, IRCCS, Milan, Italy.

Sara Gandini (S)

Department of Experimental Oncology, IEO, European Institute of Oncology, IRCCS, Milan, Italy.

Marta Cremonesi (M)

Unit of Radiation Research, IEO, European Institute of Oncology, IRCCS, Milan, Italy.

Vincenzo Positano (V)

Department of Information Engineering, University of Pisa, Pisa, Italy; Gabriele Monasterio Foundation, Pisa, Italy.

Barbara Alicja Jereczek-Fossa (BA)

Division of Radiation Oncology, IEO, European Institute of Oncology, IRCCS, Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH